A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to ascertain whether there is evidence of longer
survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control
Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to
control Arm.